cas 59489-71-3|| where to buy 5-bromopyrazin-2-amine

Produktname:5-bromopyrazin-2-amine

IUPAC Name:5-bromopyrazin-2-amine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM104262-100g	in stock	ĽǊ
CM104262-500g	in stock	ǵǤǵ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 59489-71-3 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:59489-71-3; Molekulare Formel:C4H4BrN3; Schmelzpunkt:-; SMILES-Code:NC1=NC=C(Br)N=C1; Dichte:

: Katalognummer:CM104262; Molekulargewicht:174; Siedepunkt:274.2°C at 760 mmHg; Mdl-Nr.:MFCD00235015; Lagerung:Keep in dark place, store at 2-8°C.

: Pyrazines; Pyrazine is a heterocyclic aromatic organic compound with chemical formula C4H4N2. The marketed pyrazine drugs are mainly distributed in the field of anti-tumor and anti-infection. In recent years, there have been many new drugs in various fields, and there are some new target drugs worthy of attention.; pyrazine,pyrazine price; if you want to know the latest news about pyrazine and pyrazine price, please come to our website and get a quote for free.

: Zegocractin; CalciMedica announces positive topline data from phase 2b CARPO trial of Auxora™ in Acute Pancreatitis (AP). The trial met primary objective with statistically significant dose response. Calcium release–activated calcium (CRAC) channels are involved in activating T cells, and responsible for regulating calcium-dependent inflammatory pathways or tissue cell injury pathways. AP is a potentially life-threatening inflammatory disease of the pancreas featured by aberrant signaling of calcium.
CalciMedica’s Auxora is a potent and selective intravenous formulated CRAC channel inhibitor containing the active ingredient Zegocractin. It is being developed for the treatment of acute inflammatory and immunologic illnesses, including severe AP, AIPT, AKI, and severe acute respiratory diseases including AHRF, and ARDS.